Your browser is no longer supported. Please, upgrade your browser.
Settings
ONCS OncoSec Medical Incorporated daily Stock Chart
ONCS [NASD]
OncoSec Medical Incorporated
Index- P/E- EPS (ttm)-4.04 Insider Own1.00% Shs Outstand10.29M Perf Week0.00%
Market Cap21.51M Forward P/E- EPS next Y-1.85 Insider Trans-4.27% Shs Float8.97M Perf Month16.76%
Income-32.50M PEG- EPS next Q-0.67 Inst Own21.20% Short Float3.12% Perf Quarter-7.52%
Sales- P/S- EPS this Y56.00% Inst Trans- Short Ratio3.11 Perf Half Y-6.28%
Book/sh1.44 P/B1.45 EPS next Y30.20% ROA-115.60% Target Price7.50 Perf Year-70.90%
Cash/sh- P/C- EPS next 5Y- ROE-152.00% 52W Range1.60 - 9.46 Perf YTD15.47%
Dividend- P/FCF- EPS past 5Y19.40% ROI- 52W High-78.01% Beta2.13
Dividend %- Quick Ratio2.80 Sales past 5Y- Gross Margin- 52W Low30.00% ATR0.15
Employees37 Current Ratio2.80 Sales Q/Q- Oper. Margin- RSI (14)58.10 Volatility11.14% 6.62%
OptionableNo Debt/Eq0.00 EPS Q/Q33.20% Profit Margin- Rel Volume1.09 Prev Close2.09
ShortableYes LT Debt/Eq0.00 EarningsJan 17 Payout- Avg Volume89.90K Price2.08
Recom2.00 SMA207.72% SMA504.50% SMA200-20.81% Volume86,389 Change-0.48%
Nov-07-18Downgrade H.C. Wainwright Buy → Neutral $4 → $1
Feb-09-18Initiated Piper Jaffray Overweight $4
Jul-21-16Resumed Rodman & Renshaw Buy $6
Jul-21-16Reiterated Maxim Group Buy $17 → $5
Jun-16-15Reiterated Maxim Group Buy $60 → $17
Jan-28-20 08:30AM  OncoSec Urges Shareholders Not to Fall for Alphas Disingenuous "Proposal" and Scheme to Prevent Fair Vote at Special Meeting Business Wire
Jan-27-20 11:00AM  Alpha Holdings Renews Superior, $39.3 Million Offer to OncoSec Business Wire +12.97%
08:30AM  Data from OncoSec's Visceral Lesion Applicator (VLA) to be Presented at the Society of Interventional Oncology Annual Meeting PR Newswire
Jan-21-20 04:30PM  OncoSec Announces the Appointment of Robert J. DelAversano, C.P.A, as Principal Accounting Officer and Controller Business Wire
08:30AM  OncoSec Sends Letter Urging Shareholders Not to Be Distracted by Alphas Last-Ditch Efforts to Derail CGP/Sirtex Transaction Business Wire
Jan-17-20 09:30AM  Alpha Holdings Comments on OncoSecs Failure to Consider Superior Financing Proposal Business Wire
Jan-16-20 08:30AM  OncoSec Board Rejects Alpha Holdings "Proposal" and Announces New Special Meeting Date Business Wire
Jan-15-20 12:38PM  INSERTING and REPLACING Alpha Holdings Sends Open Letter to OncoSec Stockholders Answering Questions on Proposed Financing Business Wire
Jan-14-20 08:30AM  Alpha Holdings Makes Superior, $39.3 Million Offer to OncoSec Business Wire
Jan-07-20 04:30PM  Alpha Holdings Urges Oncosec Stockholders to Vote Against China Grand Takeover on Blue Proxy Card Business Wire
Jan-06-20 08:30AM  OncoSec Sends Letter to Shareholders Highlighting that Both Leading Independent Proxy Advisory Firms ISS and Glass Lewis Have Recommended That OncoSec Shareholders Vote "FOR" the CGP/Sirtex Transaction on the WHITE Proxy Card Business Wire
Dec-30-19 08:45AM  Alpha Holdings Highlights Benefits of Its Alternate Financing Proposal for OncoSec Business Wire
Dec-26-19 08:43AM  Alpha Holdings Comments on ISS Report Business Wire
08:30AM  Institutional Shareholder Services Inc. ("ISS") Recommends OncoSec Shareholders Vote "FOR" the CGP/Sirtex Transaction Business Wire
Dec-20-19 03:16PM  OncoSec Responds to Alphas "Proposal" Business Wire -5.95%
10:03AM  Alpha Holdings Proposes $30 Million in Alternate Financing for OncoSec Business Wire
09:00AM  OncoSec Releases Presentation Spotlighting the Benefits of the Proposed CGP/Sirtex Transaction and Partnership Business Wire
Dec-18-19 08:32AM  Alpha Holdings Files Shareholder Presentation on Opposition to Proposed China Grand Takeover of OncoSec Business Wire
Dec-17-19 06:30PM  Alpha Holdings Sends Open Letter to OncoSec Stockholders Business Wire
Dec-16-19 08:30AM  OncoSec to Receive Approximately $885,000 Through New Jersey Technology Business Tax (NOL) Program PR Newswire -7.92%
Dec-13-19 08:30AM  OncoSec Presents Interim Data of 28.5% Objective Response Rate (ORR) from Ongoing KEYNOTE-890 Study Evaluating TAVO in Combination with KEYTRUDA® for Heavily Pretreated, Late-Stage, Metastatic Triple Negative Breast Cancer (mTNBC) at the 2019 San Antonio Breast Cancer Symposium PR Newswire -16.18%
Dec-12-19 08:30AM  OncoSec CEO Sends Letter to Fellow Shareholders Business Wire
Dec-09-19 08:30AM  OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value Business Wire +5.80%
Dec-06-19 12:30PM  Alpha Holdings Urges OncoSec Stockholders to Vote Against China Grand Takeover Proposal at Special Meeting of Stockholders Business Wire
Dec-05-19 09:46AM  Alpha Holdings Comments on OncoSecs Inability to Defend China Grand Takeover Business Wire
Dec-04-19 09:00AM  OncoSec Comments on Disturbing Elements of Alpha Holdings Revised Preliminary Proxy Filing Business Wire
Dec-02-19 08:00AM  OncoSec Sets the Record Straight on Alpha Holdings False and Misleading Statements Business Wire
Nov-27-19 08:30AM  Alpha Holdings Wins in Nevada Court and Comments on OncoSecs Cynical Attempt to Push Through China Grand Deal Business Wire +8.90%
Nov-26-19 08:30AM  OncoSec to Present at the 31st Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-20-19 09:15AM  Alpha Holdings Opposes OncoSec Defendants Motions to Dismiss Shareholder Class Action Complaint Business Wire
Nov-15-19 08:56AM  Alpha Holdings Provides Update on Opposition to OncoSec Takeover Proposal Business Wire
Nov-12-19 08:30AM  OncoSec Presents Immunological Data Associated with Positive Tumor Response from TAVO KEYNOTE Studies Evaluating Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting PR Newswire
Nov-05-19 08:30AM  OncoSec to Present TAVO Immune Biomarker Data Associated with Positive Clinical Response from Ongoing KEYNOTE Studies at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting PR Newswire
Oct-30-19 12:44PM  Alpha Holdings Files Class Action and Books and Records Lawsuits Against OncoSec Business Wire
Oct-21-19 09:00AM  OncoSec Provides Letter to Shareholders Regarding Recently-Announced $30 Million USD Strategic Investment at a Premium to Market PR Newswire +9.38%
Oct-15-19 08:30AM  OncoSec Announces New Peer-Reviewed Data for TAVO in Virus-Associated Skin Cancer Published in Clinical Cancer Research PR Newswire
Oct-10-19 03:09PM  4 Stocks With More Than 20% Price Increases on Thursday GuruFocus.com +34.76%
08:30AM  OncoSec Announces $30 Million USD Strategic Investment at a Premium to Market by China Grand Pharmaceutical and Healthcare Holdings (CGP) in Connection with Exclusive License to TAVO in Greater China and 35 Other Asian Countries PR Newswire
Sep-26-19 08:00AM  OncoSec to Present at the Cantor 2019 Global Healthcare Conference PR Newswire
Sep-20-19 08:00AM  OncoSec to Present at the Ladenburg Thalmann 2019 Healthcare Conference PR Newswire
Sep-06-19 08:00AM  OncoSec to Present at the 21st Annual H.C. Wainwright Global Investment Conference PR Newswire
Jul-29-19 08:40AM  OncoSec Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Application with Claims Covering Cytokine-Based Intratumoral Immunotherapies PR Newswire
Jul-16-19 08:30AM  OncoSec Issues Letter to Shareholders PR Newswire +8.52%
Jun-27-19 08:30AM  OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers PR Newswire
Jun-17-19 08:30AM  OncoSec Announces Research Collaboration with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy (IVM), TAVO-PLUS and APOLLO Electroporation Generator PR Newswire
Jun-13-19 08:30AM  OncoSec to Present Immunological Data at World Pharma Week 2019 PR Newswire
Jun-07-19 10:25AM  Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix Zacks
Jun-06-19 06:42AM  Bet on 5 Top Stocks With Rising P/E Zacks +7.47%
May-29-19 08:30AM  OncoSec Announces Collaboration For TAVO In Australia With Emerge Health PR Newswire -7.75%
May-28-19 08:30AM  OncoSec Medical Incorporated Announces Closing of $11.0 Million Public Offering and Terminates ATM and Other Financing Facility PR Newswire
May-24-19 01:46PM  Secondary Offerings Put A Pause On May's Momentum Benzinga
May-23-19 08:30AM  UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec's TAVO, Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer PR Newswire
May-22-19 09:44AM  OncoSec Medical (ONCS) Looks Good: Stock Adds 6.6% in Session Zacks -32.50%
08:45AM  OncoSec Medical Incorporated Prices $11,000,000 Public Offering PR Newswire
08:30AM  OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer PR Newswire
02:44AM  Why These Stocks Are On The Move Insider Monkey
May-21-19 04:01PM  OncoSec Medical Incorporated Announces Proposed Public Offering PR Newswire +6.64%
08:30AM  OncoSec Granted Exclusive Worldwide Rights To A Patent Portfolio For The Combination Use Of IL-12 DNA With Checkpoint Inhibitors To Treat Cancer In Several Key Countries PR Newswire
May-20-19 12:45PM  OncoSec Announces 1-for-10 Reverse Stock Split PR Newswire -16.61%
Apr-29-19 08:00AM  OncoSec to Present at ThinkEquity Conference 2019 PR Newswire
Apr-28-19 09:59AM  If You Had Bought OncoSec Medical (NASDAQ:ONCS) Stock Five Years Ago, You'd Be Sitting On A 96% Loss, Today Simply Wall St.
Apr-24-19 08:00AM  OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to it's Board of Directors PR Newswire
Apr-23-19 08:00AM  OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO, Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer PR Newswire
Apr-17-19 08:00AM  OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center PR Newswire
Apr-10-19 08:00AM  OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12 PR Newswire
Apr-09-19 08:00AM  OncoSec to Present at H.C. Wainwright Global Life Sciences Conference PR Newswire
Apr-08-19 08:00AM  OncoSec's KOL Symposium Sheds New Light on the Importance of IL-12 Use Via OncoSec's Technology and Provides Updates on TAVO's Clinical Progress PR Newswire
Apr-02-19 08:00AM  OncoSec Presents Promising Preclinical Data with New Product Candidate and Improved Electroporation Generator at AACR Annual Meeting PR Newswire +9.12%
Apr-01-19 08:00AM  OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO in Refractory Metastatic Melanoma PR Newswire +10.23%
Mar-27-19 08:16AM  OncoSec To Host Key Opinion Leader Symposium On April 5, 2019 PR Newswire
Mar-13-19 08:30AM  OncoSec to Present at the 31st Annual ROTH Conference PR Newswire
Feb-28-19 08:00AM  OncoSec Announces Poster Presentation at 2019 American Association for Cancer Research Annual Meeting PR Newswire
Feb-08-19 08:00AM  OncoSec To Present At BIO CEO & Investor Conference PR Newswire
Jan-22-19 08:00AM  OncoSec to Host 2019 Business Outlook Conference Call on February 1, 2019 PR Newswire -5.49%
Jan-07-19 08:30AM  OncoSec and Gynecologic Oncology Group (GOG) Foundation, Inc. to Conduct a Pivotal Study of TAVO with Standard of Care KEYTRUDA® for Treatment of Late Stage Cervical Cancer PR Newswire +8.56%
Dec-21-18 08:30AM  OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of Directors PR Newswire
Dec-18-18 08:30AM  OncoSec Announces Publication of New Research in the Journal Immunity Highlighting the Role of IL-12 in Anti-PD-1 Therapies with TAVO Directly Activating TILs in Patients PR Newswire -6.74%
Dec-12-18 08:00AM  OncoSec Reports Updated Tumor Responses in KEYNOTE-695 Study of TAVO + KEYTRUDA® in Refractory Metastatic Melanoma PR Newswire
Dec-11-18 08:30AM  OncoSec Presents New Data Showing A Single Cycle Of Monotherapy TAVO Can Generate Productive Immune Responses In Triple Negative Breast Cancers (TNBC) PR Newswire -6.19%
Dec-10-18 08:30AM  OncoSec Receives $7 Million Investment From Alpha Holdings At $1.50 Per Share PR Newswire +8.49%
Dec-03-18 02:22PM  Analysts Expect Breakeven For OncoSec Medical Incorporated (NASDAQ:ONCS) Simply Wall St.
Nov-29-18 08:00AM  OncoSec Presents New Data During Oral Presentation At Melanoma Bridge Demonstrating Intratumoral Monotherapy TAVO Induces Abscopal Responses In Metastatic Melanoma Patients PR Newswire
Nov-20-18 08:00AM  OncoSec to Present at Piper Jaffray 30th Annual Healthcare Conference PR Newswire
Nov-13-18 08:00AM  OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium® PR Newswire
Nov-08-18 08:00AM  OncoSec Appoints Robert Ward to its Board of Directors PR Newswire
Nov-07-18 08:00AM  OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial PR Newswire
06:55AM  Todays Research Reports on Stocks to Watch: Vericel and OncoSec Medical ACCESSWIRE
Nov-06-18 08:00AM  OncoSec Reports Preliminary Data from KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial of TAVO in Combination with KEYTRUDA® for Metastatic Melanoma at Society for Immunotherapy of Cancer's 33rd Annual Meeting PR Newswire -49.82%
Nov-05-18 08:00AM  OncoSec to Host Conference Call to Review Preliminary KEYNOTE-695 Data PR Newswire -7.45%
Nov-02-18 08:00AM  Today's Research Reports on Trending Tickers: Alexion Pharmaceuticals and OncoSec Medical ACCESSWIRE
08:00AM  OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting PR Newswire
Oct-29-18 08:00AM  OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer PR Newswire -7.34%
Oct-24-18 08:00AM  OncoSec Announces Publication of Data in Nature Gene Therapy Demonstrating the Ability of its Newly Optimized Intratumoral IL-12 Immunotherapy Platform to Increase Systemic Anti-tumor Responses in both Treated and Untreated Lesions PR Newswire -6.74%
Oct-15-18 07:30AM  OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Late-Stage Triple Negative Breast Cancer PR Newswire
Oct-09-18 08:00AM  OncoSec Announces Closing of First Tranche of $15 Million At Market Investment from Alpha Holdings, Inc. PR Newswire
Oct-08-18 08:00AM  OncoSec Chief Scientific Officer to Present at Advances in Immuno-Oncology USA Congress PR Newswire -5.36%
Oct-02-18 08:00AM  Data from OncoSec's OMS-100 Clinical Trial Accepted for Oral Presentation at the 2018 Melanoma Bridge Conference PR Newswire
Sep-25-18 07:30AM  OncoSec to Present at Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-04-18 07:30AM  OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc. PR Newswire
Aug-31-18 08:00AM  OncoSec to Present at H.C. Wainwright 20th Annual Global Investment Conference PR Newswire
OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the Phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company is developing new DNA-encoded therapeutic candidates and tumor indications. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a collaborative research agreement with Duke University School of Medicine to evaluate TAVOPLUS; a collaboration with Dana-Farber Cancer Institute and the Marasco Laboratory to develop CAR T-cell therapies for triple-negative breast cancer and ovarian cancer; and a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and TAVO. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bonstein SaraCFO/COOJan 16Sale2.081,3512,81041,389Jan 21 04:15 PM
O'Connor Daniel J.CEO and PresidentOct 31Sale2.162,1284,59668,715Nov 01 08:00 PM
Bonstein SaraCFO/COOOct 16Sale2.011,1112,23342,740Oct 18 08:00 PM
Alpha Holdings, Inc.DirectorJul 17Buy2.5730,00077,1001,611,000Jul 19 09:55 PM
Alpha Holdings, Inc.DirectorJul 16Buy2.3460,000140,4001,581,000Jul 17 09:55 PM
Alpha Holdings, Inc.DirectorJul 15Buy2.2230,00066,6001,521,000Jul 17 09:55 PM
Alpha Holdings, Inc.DirectorMay 22Buy3.14491,0001,541,74010,491,000May 24 05:30 PM